Blood cancers

AACR 2018: Novel immunotherapy shows promise in refractory non-Hodgkin lymphoma

Patients with indolent non-Hodgkin lymphoma (iNHL) refractory to current standard of care ‘mAbs’ therapies may get augmented responses with a novel cytokine IL15 immunotherapy, early studies in humans suggest. In phase I trial findings presented at the American Association of Cancer Research 2018 annual meeting in Chicago, researchers from the Washington University School of Medicine ...

Already a member?

Login to keep reading.

© 2021 the limbic